Nuvation Bio Inc. reported a net loss of $55.8 million, or $(0.16) per share, for the third quarter ended September 30, 2025, compared to a net loss of $41.2 million, or $(0.15) per share, in the same period in 2024. Selling, general, and administrative expenses rose to $37.4 million from $19.6 million, primarily due to higher personnel-related costs, increased sales and marketing expenses, and investments in systems for the commercial launch of taletrectinib. As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $549.0 million. Nuvation Bio began shipping IBTROZI to U.S. customers in June 2025, generating net product revenue of approximately $7.7 million for the quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103661962) on November 03, 2025, and is solely responsible for the information contained therein.